The National Comprehensive Cancer Network (NCCN) recommends that a repeat bone marrow evaluation is carried out seven to ten days following completion of induction therapy so that if a patient's day 14 bone marrow shows residual blast cell counts of >10%, the patient would proceed early to a second cycle of induction therapy. Although blast cell counts of <5% on day 14 bone marrow is sensitive in predicting remission on day 28, various studies have found that day 14 bone marrow is highly nonspecific because a large proportion of patients with blast cell counts of >5% on day 14 bone marrow would still attain a complete remission of the disease without any further chemotherapy. Clinical decision based on day 14 bone marrow will result in some of these patients being given a second induction therapy unnecessarily. A second cycle of chemotherapy is associated with not only higher risk for treatment-related mortality but also increased use of hospital resources such as increased intravenous antimicrobials use, longer hospital stay, and higher demand for blood products. In this article, we examined the utility, discussed the shortfalls, and reappraised the values of day 14 bone marrow in the management of patients with AML. On the basis of our review, we suggest that the practice of day 14 bone marrow examination should be re-evaluated and should probably only be carried out in the setting of clinical trials with clear questions to address its role in predicting outcome of the therapeutic intervention.
| I N T R O D U C T I O N
Despite advances in modern chemotherapeutic agents, the prognosis of patients with acute myeloid leukemia (AML) remains poor. Using standard induction chemotherapy with three days of an anthracycline and seven days of standard dose cytarabine ("3 1 7" regimen), only 65%-70% of adult patients under the age of 60 can expect to attain a complete remission of their disease. The remission rate in older patients is significantly lower, in the region of 40%-45%. It is, therefore, not surprising that various therapeutic strategies have been employed to improve on these results, especially in older patients.
Although remission rates were increased using some of these strategies, the long-term outcomes have uniformly not changed. In addition to using different induction chemotherapy regimens, various methods have also been employed to detect residual disease following chemotherapy so that early intervention, in the form of a second cycle of induction chemotherapy, can be administered to these patients to, perhaps, improve the clinical outcome. The detection methods include multicolor flow cytometric analysis, molecular analysis using polymerase chain reaction for specific targets, and the analysis of bone marrow seven to ten days after completing the induction chemotherapy ("Day 14" bone marrow).
For more than two decades, day 14 bone marrow has been widely used in the routine management of AML patients following induction therapy. It is a very attractive approach since morphologic evaluation of residual disease in the bone marrow can easily be performed. Its use is, therefore, not limited by the availability of high tech instrumentation. It is also inexpensive. The National Comprehensive Cancer Network (NCCN) recommends that morphologic evaluation of bone marrow be carried out seven to ten days following completion of induction therapy. 1 If a patient's day 14 bone marrow is hypoplastic (<10%-20% cellularity) and with low residual blast count (<5%-10%), no further induction is recommended. The patient will undergo a repeat bone marrow examination upon hematologic recovery to document remission status. In patients with residual blast cell count of >10% on day 14 bone marrow, it recommends that an additional cycle of induction therapy is given early to rescue the patient and induce a complete remission of the disease after the initial induction failure.
Day 14 bone marrow is, however, notoriously nonspecific. Consequently, the necessity of day 14 bone marrow is being questioned and, 
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based on personal observation, the practice being foregone by increasingly more physicians treating AML patients. To assess the validity of such a practice, we have, in this review, examined the utility, discussed the shortfalls, and reappraised the values of day 14 bone marrow in the management of patients with AML. Retrospective D14 BM hypocellularity the most significant predictor of CR (P < 0.001). Absolute blast reduction of >50% (P 5 0.030), and de novo disease status (P 5 0.018) significantly correlated with CR after re-induction. The choices for the cut-offs were based on receiver operating curve (ROC) analysis that showed the highest accuracy in terms of specificity and sensitivity. Nevertheless, of the 124 patients who were under 60 years of age, 79% of those with <22% blast cell count on the day 14 bone marrow achieved a complete remission of their disease. For those 74 patients who were 60 years or older treated on the AML13 protocol, the remission rate was 67% in patients whose day 14 bone marrow showed <15% blast cell infiltrate.
| U T IL I T Y OF DA Y 1 4 B O N E M AR R O W TO P R E D I C T RE M I S S I O N
To increase the sensitivity of day 14 bone marrow in predicting complete remission, the threshold blast cell counts were reduced in various studies. A single-center study examined the utility of day 14 bone marrow in a group of 82 AML patients who had both day 14 bone marrow and recovery bone marrow. 4 These patients received induction therapy either with the "3 1 7" regimen, with or without the addition of etoposide, or with fludarabine and cytarabine (FLAG regimen). The sensitivity of day 14 bone marrow that showed 5% blast cell counts in predicting complete remission by day 28 was increased to 90%. Using the threshold 5% blast cell count, a similar high sensitivity of day 14 bone marrow in predicting 95.3% complete remission was observed in 98 AML patients who were treated uniformly with the "3 1 7" regimen. 9 Interestingly, when the threshold blast cell count was reduced to <5%, there was no further increase in the sensitivity of the day 14 bone marrow. Norkin et al. 13 found in their series of 297 AML patients who received primarily the "3 1 7" regimen for induction therapy that the sensitivity of day 14 bone marrows was 88% when the threshold blast cell count was <5%. of patients with >10% blast cells attained a complete remission after cycle 2 of the induction chemotherapy, whereas remission was attained in 84% of those with blast cell counts of <10%. Therefore, early bone marrow evaluation following first cycle of induction chemotherapy also has high sensitivity for remission prediction in AML patients who received the double induction regimen.
| T H E LI M I T A T I O N S A N D SH O R T F A L L S OF DAY 14 BONE MARROW
Despite the high levels of sensitivity of residual blast cell counts of <5% in predicting disease remission on day 28, the specificity of day 14 bone marrow has been uniformly disappointing (Table 1 ). It was found that 19% of patients with more than 22% blast cell counts on day 14 bone marrow attained a complete remission without further therapy. 2 Similarly, 19% of those 60 years or older in this study attained a complete remission of their disease without further intervention when the cut-off was set at 15%.
Hussein et al. 4 found in their cohort of patients that the failure of cytoreduction (5% blast cell counts) on day 14 bone marrow only had 43% specificity in predicting treatment failure on Day 28. Yanada et al. 5 observed similar lack of specificity of day 14 bone marrow. In the cohort of 586 patients we examined, 45% of those with a day 14 bone marrow blast cell counts of 5-100% and 53% of those with blast cell count of 5-59% attained a complete remission without a second cycle of induction therapy. Yezefski et al. 12 also found, in another cohort of patients, that the decision to perform a day 14 bone marrow did not influence the complete remission rates. Norkin et al. 13 reported that, despite the presence of residual disease on day 14 bone marrow, of the 89 patients who did not receive a second cycle of induction therapy, 32 patients (36%) subsequently entered a complete remission of their disease. Based on these results, if a second cycle of induction chemotherapy is automatically given to patients with residual disease on day 14 bone marrow, 35%-50% of these patients may have been reinduced unnecessarily.
Ideally, patients should emerge from the induction therapy in a condition that allows them to tolerate further intense consolidation regimens, including allogeneic stem cell transplant in some cases, to improve the long-term survival. A second cycle of induction given before hematologic recovery will predispose patients to prolonged periods of deconditioning, especially in the older patients, and pancytopenia that will increase risks for complications such as life-threatening infections and bleeding. It has been well documented that treatmentrelated mortality is significantly higher during second cycle of induction therapy than first cycle (1.8% vs. 6.8%). 8 Patients given a second cycle of induction therapy also impose enormous economic impacts due to increased use of blood products and systemic antimicrobials and prolonged lengths of stay in the hospital.
On the other hand it is known that the less measurable disease (MRD) a patient has before allogeneic stem cell transplant the less the risk of relapse. Hence, it may be reasonable for some patients in CR based on blood counts and marrow morphology after course 1 but with MRD to receive a 2nd cycle of chemotherapy, even though it remains unclear how many of them would eradicate the MRD with the 2nd cycle of chemotherapy. Hence an assessment of the potential benefits must be weighed against the risks associated with a 2nd cycle of induction therapy.
| P R E D I C T I N G RE M IS S ION : B E Y O N D DA Y 1 B O N E M A R RO W B LA S T C O U NTS
The lack of specificity of day 14 bone marrow blast cell counts has prompted various investigators to examine other prediction models of remission. We previously investigated whether the specificity of day 14 bone marrow blast cell counts could be improved when supplemented with day 21 bone marrow. 5 Although approximately half of patients with 20-59% blast cell counts on day 14 bone marrow had <20% blast cell counts on day 21 and that 62% of them attained a complete remission without a second cycle of induction therapy, day 21 bone marrow did not alter the decision to begin cycle 2 of induction therapy in patients whose day 14 bone marrow had too few cells to count, <20% blast cells, or 60% blast cells. Norkin et al. 13 proposed a model to predict remission status by combining day 14 bone marrow blast cell counts with clinical and laboratory characteristics of de novo or relapsed AML, and good or high risk AML, based on cytogenetics, history of antecedent hematologic diseases, and treatment-related disease. The specificity of day 14 bone marrow was increased to 93%, but at the expanse of a much-reduced sensitivity at 78%. The specificity of early bone marrow biopsy in predicting remission was also increased to 88.2% if the bone marrow was carried out on day 5 instead of day 14. 11 As one would expect, the increased specificity came with a much reduced sensitivity because day 5 bone marrow failed to identify slow responders to the induction therapy.
Instead of blast cell counts, the bone marrow cellularity was found in a retrospective study to be the most important predictor of remission in those who required a second induction chemotherapy based on day 14 bone marrow blast cell counts. 14 However, since we previously found in the group of patients whose day 14 bone marrow was classified as "too few cells to count" due to hypocellularity) that only 71% of these patients attained a complete remission without a second cycle of induction therapy, 5 it is highly likely that day 14 bone marrow cellularity will have low sensitivity and specificity in predicting remission after the first cycle of induction therapy. Additionally, estimation of marrow cellularity is, to a considerable extent, subjective Serial examinations of the peripheral blood during induction therapy have been investigated to determine whether this could be used to predict remission. Using flow cytometric analysis for the blast cells in the peripheral blood, a less than two log reduction in the blast cells by day 5 of induction therapy, 15 the day of 90% reduction in the circulating blast cells, 16 and day 7 peripheral blood blast percentages 17 have all been found to correlate with treatment failure. However, how well these methods compare against day 14 bone marrow in sensitivity and specificity in predicting remission remains unknown.
| RESIDUAL DISEASE ON DAY 14 BONE MARROW AND CLINICAL OUTCOME IN AML
Although residual disease on day 14 bone marrow has limited specificity for disease remission on day 28, it may influence clinical outcome beyond remission. In the German AML Cooperative Group (AMLCG) 1992 trial of double induction strategy 3 in which cycle 2 of the induction therapy was started on day 21, irrespective of the findings on the day 16 bone marrow, in addition to being associated complete remission rate, day 16 bone marrow blast counts correlated with overall survival, event-free survival, and relapse-free survival. Multivariate analyses identified that day 16 blast cell counts were independent of pre-therapeutic parameters and predicts outcome. However, despite having a very high sensitivity in predicting complete remission, day 14 bone marrow was not found to impact the overall survival following single induction strategy.
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| INFLUENCE OF DAY 14 BONE MARROW-BASED THERAPEUTIC DECISION ON CLINICAL OUTCOME
The primary reason for administering a second cycle of induction therapy, if the day 14 bone marrow indicates residual disease, is the assumption that patients with residual leukemia would not achieve complete remission unless a second cycle was administered, or even if they do, the quality of the remission may be shallow. This is based on the premise that there is a lower leukemia load on day 14 compared day 28. Therefore, the earlier the second cycle of induction chemotherapy is given, the higher will be the likelihood for attaining a complete remission. Such an argument has, however, not been widely supported based on currently available data. 18 In the multicenter prospective LAM-2001 trial by the GOELAMS study group, all patients received the standard "3 1 7" regimen, but a second cycle of induction therapy in the form of intermediate-dose
cytarabine was administered to patients with 5% bone marrow blast cell counts 15 days after the initiation of the first cycle of induction therapy. 8 In-spite of a second cycle of induction therapy, patients with 5% blast cell counts on day 15 bone marrow still had poorer 5-year event-free survival, relapse-free survival and overall survival, in addition to a lower complete remission rate, raising questions about the exact benefits of the second cycle of induction therapy in these patients. It is, therefore, likely that detecting residual disease on the day 14 bone marrow identifies a group of AML patients with poorer prognosis, rather than an indication that a second cycle of induction therapy is warranted.
One could also make the argument that in some of these patients with residual leukemia on day 14 bone marrow and who would attain a remission without further chemotherapy, two cycles of induction would induce a "deeper" remission. Perhaps two cycles of induction therapy closer together may also have synergistic effect. A retrospective cohort study that involved six AML clinical trials conducted by the Eastern Cooperative Oncology Group (ECOG) instead found identical disease outcomes, irrespective of whether the remission was attained with one or two cycles of induction therapy. 6 Tallman et al. 19 also demonstrated that patients who were in complete remission after a single induction and proceeded to HLA-identical sibling transplantation did not benefit from post-remission consolidation with cytarabine when compared to proceeding directly to allogeneic transplantation. Both these studies raise questions on the concept of "deeper" remission and may suggest that if the patients are treated with the appropriate postremission therapy, the depth of remission following induction therapy, when judged by bone marrow morphology, may not be as important.
| C O NC LU S I O N S
In summary, although blast cell counts on day 14 bone marrow is highly sensitive in predicting remission on day 28, they lack specificity so that a significant proportion of patients with residual disease on day 14 bone marrow would still attain a complete remission of their disease without a second cycle of induction therapy. Furthermore, it is not all clear decisions based on day 14 findings affect outcome. The lack of specificity is likely due to three reasons. First, the inability to identify covariates associated with resistance is an important factor. This is observed even when multivariate models incorporating sophisticated genetic information are used, as quantified by area under receiver operating characteristic curves, in prognosticating resistance. 20 Second, it remains problematic our ability to identify slow responders, either unique of a certain patient group, AML of certain biology, or to the kinetics of leukemia cell kill from different chemotherapeutic agents used in the induction therapy. Finally, there is not the slightest doubt that there is inter-and intraobserver variability in assessing blast cells by morphology alone; the confidence interval for an actual blast cell count of 5% ranged widely from 1 to 12% for a 100-cell differential.
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A study is currently ongoing to determine whether PET scan would be more specific and sensitive than Day 14 bone marrow in predicting remission following induction chemotherapy (NCT02392429).
Although the prognostic value of day 14 bone marrow in AML is supported by various studies, it remains unclear whether intervention with a second induction therapy based on day 14 bone marrow alters the outcome. It is highly probable that residual disease on day 14 bone marrow simply identify a group of AML patients who are going to have poorer outcome irrespective of intervention, in which case, day 14 bone marrow becomes more of a surrogate marker of poor prognosis, than an actionable finding.
If day 14 bone marrow is to be used for prognostication, other less subjective methods for prognostication may be preferred. One such approach involves multi-parametric flow cytometry, which uses a leukemia-associated immunophenotype to assess minimal residual disease (MRD). 22 van der Velden et al. 23 identified aberrant immunophenotypes in 94% of 94 pediatric AML patients and demonstrated that the level of MRD after the first course of chemotherapy provided prognostic information. Buccisano et al. 24 proposed combining posttreatment MRD detection with pretreatment cytogenetics/genetics.
The AML02 multicenter trial utilized flow cytometry-based MRD analysis along with genetic abnormalities to develop a risk-based approach to direct therapy in children with acute myeloid leukemia. 25 The use of molecular analysis, including next generation sequencing may be the future for guiding therapeutic decisions and will likely be more objective and of higher precision, although we have also found that the use of flow cytometry to detect residual disease on Day 14 bone marrow did not improve the specificity of day 14 bone marrow when compared to evaluation by morphology alone. 26 We suggest the routine use of day 14 bone marrow in the management of AML be re-evaluated, especially outside the context of clinical trials, and should not be used for decision-making on whether to introduce a second cycle of induction therapy. It should probably only be incorporated in clinical trials if there are clear questions being posed to address its role in predicting outcome of the therapeutic intervention.
